Should I invest in Nippon India Nifty Pharma ETF?

We don't give personal investment advice. Nippon India Nifty Pharma ETF is suitable for an investor whose:understands what asset class this scheme actually invests in (check the factsheet)matches that asset class's volatility profile to their goal horizonCross-check the numbers above against alternatives before deciding. 5-year CAGR: 11.31%.

Nippon India

Nippon India Nifty Pharma ETF

Latest NAV

₹24.7084

As of

3 Jun 2026

1,212 NAV records on file

NAV history & peer comparison

All NAVs split-adjusted and normalised to 100 at the start of the selected period, so funds with very different absolute NAV scales can be compared on one axis.

Period

Add another fund to compare

No matches.

Compares up to 8 funds. Click any line in the legend above to hide/show it.

Returns matrix

Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).

Window	Fund	Category avg	+/− vs avg	Rank	Quartile
1D	-0.86%	+0.40%	-1.26	272 / 278	Q4
1W	-2.63%	-1.18%	-1.45	239 / 277	Q4
2W	-3.45%	+0.22%	-3.67	265 / 276	Q4
1M	+2.27%	+0.13%	+2.14	36 / 272	Q1
3M	+4.54%	-0.73%	+5.27	40 / 268	Q1
6M	+4.96%	-0.31%	+5.27	36 / 255	Q1
YTD	+6.24%	-2.50%	+8.73	33 / 258	Q1
1Y	+12.79%	+10.97%	+1.82	35 / 226	Q1
2Y	+13.32%	+6.94%	+6.37	23 / 179	Q1
3Y	+23.58%	+14.13%	+9.45	18 / 147	Q1
4Y	+18.51%	+13.79%	+4.72	23 / 116	Q1
5Y	+11.31%	+10.71%	+0.60	27 / 89	Q2
7Y	—	—	—	—	—
10Y	—	—	—	—	—
Inception	+11.53%	+11.30%	+0.24	110 / 278	Q2

Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%

Calendar-year returns

Full-year performance vs category average. Current year is partial (year-to-date).

Year	Fund	Category avg	+/− vs avg	Rank
2026 YTD	+6.24%	-2.52%	+8.75	33 / 257
2025	-2.65%	+16.95%	-19.61	171 / 192
2024	+39.37%	+15.68%	+23.69	6 / 155
2023	+35.16%	+24.57%	+10.59	25 / 133
2022	-10.86%	+3.53%	-14.39	92 / 104
2021	—	—	—	—

Rolling returns

Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.

1-Year rolling

+16.25%

48 windows

min -13.3% · max 63.3%

69% positive

Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.

3-Year rolling

+19.62%

24 windows

min 13.2% · max 24.9%

100% positive

Limited basis — fund is young, so this average may be skewed by which 3Y windows happen to be available.

5-Year rolling

—

Insufficient history

7-Year rolling

—

Insufficient history

SIP returns — historical "what if"

If you had invested every month in this fund over the chosen period, this is what your investment would be worth today.

Period

Total invested

₹ —

Today's value

₹ —

XIRR

Annualised

Wealth multiplier

Period	Total invested	Today's value	XIRR	Wealth multiplier

XIRR is the annualised internal rate of return on the SIP cash flow — invariant to the monthly amount. "Today's value" and "Total invested" scale linearly with the slider. Past performance does not guarantee future returns. Excludes exit load and taxes.

Risk profile

Risk-adjusted return and volatility, computed from monthly NAV returns over the trailing 3-year and 5-year windows.

Std deviation

15.87%

3-year · annualised

Sharpe ratio

1.02

vs risk-free 6.5%

Sortino ratio

1.93

Downside-only deviation

Max drawdown

-16.55%

Oct 2024 → Feb 2025

% positive months

63.9%

Share of monthly returns > 0 over the 3-year window

Sharpe / Sortino use a risk-free rate of 6.5% (1-year T-bill proxy). Higher Sharpe = more return per unit of total risk; higher Sortino = more return per unit of downside risk.

Peers in ETF

Scheme	Fund house	NAV	As of
HDFC NIFTY PSU BANK ETF	HDFC	₹82.8791	3 Jun 2026
Nippon India ETF Nifty Bank BeES	Nippon India	₹559.5032	3 Jun 2026
SBI BSE PSU BANK ETF	SBI	₹47.6181	3 Jun 2026
ICICI Prudential Nifty Auto ETF	ICICI Prudential	₹26.8992	3 Jun 2026
Aditya Birla Sun Life Nifty Bank ETF	Aditya Birla Sun Life	₹55.3934	3 Jun 2026
Motilal Oswal BSE Healthcare ETF	Motilal Oswal	₹47.0809	3 Jun 2026
Mirae Asset BSE India Defence ETF	Mirae Asset	₹75.1403	3 Jun 2026
Kotak Nifty Bank ETF	Kotak	₹56.0814	3 Jun 2026
Kotak PSU Bank ETF	Kotak Mahindra	₹820.4532	3 Jun 2026
DSP Nifty Bank ETF	DSP	₹55.3202	3 Jun 2026

Recent NAVs

Date	NAV
3 Jun 2026	₹24.7084
2 Jun 2026	₹24.6262
1 Jun 2026	₹24.8395
29 May 2026	₹24.9748
27 May 2026	₹25.3499
26 May 2026	₹25.2918
25 May 2026	₹25.3079
22 May 2026	₹25.2050
21 May 2026	₹25.5302
20 May 2026	₹25.4814

Frequently asked questions

These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.

As of 03 Jun 2026, the NAV of Nippon India Nifty Pharma ETF is ₹24.7084. It's a ETF from Nippon India, run as a Unknown plan IDCW (dividend) option. NAVs update once per business day from the AMFI feed.

Nippon India Nifty Pharma ETF has NAV history starting from 06 Jul 2021, a track record of about 4 years 10 months. It's a relatively new scheme. With under 5 years of NAVs, peer comparison is the best yardstick — point-to-point returns can be skewed by entry timing.

Nippon India Nifty Pharma ETF is managed by Nippon India. It's classified by AMFI under the 'ETF' SEBI category, which determines its peer set and tax treatment.

Over the trailing 1-year window, Nippon India Nifty Pharma ETF has delivered a absolute return of 12.79% — +1.82 pp ahead of the ETF category average of 10.97%. The fund ranks #35 of 226 in its category — the top (Q1) quartile.

Over the trailing 3-year window, Nippon India Nifty Pharma ETF has delivered a CAGR of 23.58% — +9.45 pp ahead of the ETF category average of 14.13%. The fund ranks #18 of 147 in its category — the top (Q1) quartile.

Over the trailing 5-year window, Nippon India Nifty Pharma ETF has delivered a CAGR of 11.31% — +0.6 pp ahead of the ETF category average of 10.71%. The fund ranks #27 of 89 in its category — the second (Q2) quartile.

₹1 lakh invested in Nippon India Nifty Pharma ETF exactly 5 years ago would be worth approximately ₹170,899 today — a multiplier of 1.71×, based on the 5-year CAGR of 11.31%. The category average over the same window would have grown ₹1 lakh to ₹166,336.

A ₹10,000 monthly SIP in Nippon India Nifty Pharma ETF over the last 3 years — total invested ₹360,000 — would be worth ₹446,625 today. That's an XIRR (money-weighted annualised return) of 14.50%.

Nippon India Nifty Pharma ETF doesn't yet have 10 years of NAVs. Over the longest available window (3-year SIP), ₹10,000/month would have grown to ₹446,625 — XIRR 14.50%.

On a 5-year basis, Nippon India Nifty Pharma ETF ranks #27 out of 89 funds in the ETF category — that places it in the second quartile (Q2) — above the median. The category average return over the same window is 10.71%; this fund delivered 11.31%.

The worst peak-to-trough decline Nippon India Nifty Pharma ETF has experienced over the last 3-year window is 16.55% — its NAV fell from a high on 09 Oct 2024 to a low on 28 Feb 2025. Drawdown is a useful gauge of how much short-term pain you'd have endured to capture the long-term return.

Across all 3-year rolling windows, Nippon India Nifty Pharma ETF averaged 19.62% (best 24.87%, worst 13.15%). 100% of rolling windows ended positive. The 3-year Sharpe ratio is 1.01 — strong risk-adjusted performance.

In calendar year 2025, Nippon India Nifty Pharma ETF returned -2.65% — lagging the ETF category average of 16.95% by 19.61 pp. It ranked #171 of 192 in its category that year.

Nippon India Nifty Pharma ETF doesn't fit cleanly into the standard Equity/Debt buckets in our taxonomy. Tax treatment depends on actual asset allocation as disclosed by the AMC — check the factsheet or AMFI's classification table.

We don't give personal investment advice. Nippon India Nifty Pharma ETF is suitable for an investor whose:

understands what asset class this scheme actually invests in (check the factsheet)
matches that asset class's volatility profile to their goal horizon

Cross-check the numbers above against alternatives before deciding. 5-year CAGR: 11.31%.

Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.